Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection

According to recent investigations, the eradication of Helicobacter pylori (H. pylori) may influence levodopa (LD) pharmacokinetics (PK) and improve the motor function of infected patients with Parkinson disease (PD). The aim of this study was to compare PK of LD and its metabolite 3-O-methyldopa (3...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical neuropharmacology 2014-07, Vol.37 (4), p.96-99
Hauptverfasser:	Narożańska, Ewa, Białecka, Monika, Adamiak-Giera, Urszula, Gawrońska-Szklarz, Barbara, Sołtan, Witold, Schinwelski, Michał, Robowski, Piotr, Madaliński, Mariusz H, Sławek, Jarosław
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antiparkinson Agents - pharmacokinetics Antiparkinson Agents - therapeutic use Benserazide - therapeutic use Dihydroxyphenylalanine - analogs & derivatives Dihydroxyphenylalanine - blood Fasting Female Helicobacter Infections - blood Helicobacter Infections - complications Helicobacter pylori Helicobacter pylori - pathogenicity Humans Levodopa - pharmacokinetics Levodopa - therapeutic use Male Middle Aged Motor Activity - drug effects Parkinson Disease - blood Parkinson Disease - complications Parkinson Disease - drug therapy Severity of Illness Index Tyrosine - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!